Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.

BridgeBio Pharma's robust pipeline, favorable policy shifts, and milestone payments position it for substantial future growth ...

As the U.S. stock market rebounds from recent declines, with the Dow Jones surging over 1,000 points and tech-heavy indices like the Nasdaq Composite seeing significant gains, investors are closely ...

Over the last 7 days, the United States market has dropped 4.4%, and over the past 12 months, it has remained flat overall; however, earnings are forecast to grow by 13% annually. In this environment, ...